Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/ajh.23454 http://scihub22266oqcxt.onion/10.1002/ajh.23454 C4685468!4685468 !23605934     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 261.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 261.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 261.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\23605934 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Am+J+Hematol 2013 ; 88 (7 ): 566-70 Nephropedia Template TP {{tp|p=23605934 |t=2013. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes |pdf=|usr=}}{{23605934 }} gab.com Text Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes JO: Am J Hematol http://www.kidney.de/pget.php?&tw=1&pmid=23605934 #FOAvip The International Prognostic Scoring System (IPSS) was recently revised (IPSS-R) under the auspices of the MDS Foundation as a collaborative international effort to refine its prognostic power. Our purpose was to externally validate this new risk model using a large single-institution cohort, determine its prognostic power in patients receiving active treatment, and explore its utility in guiding therapeutic decisions. Data were collected retrospectively from our myelodysplastic syndrome (MDS) database and verified by chart review. Of the data available for 1,088 patients, 152 (14%), 353 (32%), 237 (22%), 190 (18%), and 156 (14%) patients were classified as very low, low, intermediate, high, and very high risk, respectively, with median overall survival (OS) of 90 (95%CI 71-109), 54 (95%CI 50-59), 34 (95%CI 26-43), 21 (95%CI 17-25), and 13 months (95%CI 11-15), respectively (P?<?0.005). We found that the IPSS-R further refined prognostic discrimination in all IPSS risk categories, particularly in the intermediate 1 and 2 groups. Among high and very high IPSS-R patients receiving azacitidine, OS was significantly improved versus patients not receiving azacitidine, with corresponding median OS of 25 versus 18 months (P?=?0.028) and 15 versus 9 months (P?=?0.005), respectively. Similarly, patients with IPSS-R high- and very high-risk disease who underwent allogeneic hematopoietic stem cell transplantation had significantly improved OS versus nontransplant approaches (P?<?0.005). High and very high IPSS-R patients derived a survival advantage from disease-modifying therapies. Our data validate the prognostic value of the proposed IPSS-R and show that its refined IPSS prognostic discrimination can be applied to actively treated patients. Twit Text FOAVip Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes ????Am J Hematol http://www.kidney.de/pget.php?&tw=1&pmid=23605934 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=23605934 #FOAvip English Wikipedia <ref>{{Cite pmid|23605934 }}</ref> Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes #MMPMID23605934 Mishra A ; Corrales-Yepez M ; Ali NA ; Kharfan-Dabaja M ; Padron E ; Zhang L ; Epling-Burnette PK ; Pinilla-Ibarz J ; Lancet JE ; List AF ; Komrokji RS Am J Hematol 2013[Jul]; 88 (7 ): 566-70 PMID23605934 show ga The International Prognostic Scoring System (IPSS) was recently revised (IPSS-R) under the auspices of the MDS Foundation as a collaborative international effort to refine its prognostic power. Our purpose was to externally validate this new risk model using a large single-institution cohort, determine its prognostic power in patients receiving active treatment, and explore its utility in guiding therapeutic decisions. Data were collected retrospectively from our myelodysplastic syndrome (MDS) database and verified by chart review. Of the data available for 1,088 patients, 152 (14%), 353 (32%), 237 (22%), 190 (18%), and 156 (14%) patients were classified as very low, low, intermediate, high, and very high risk, respectively, with median overall survival (OS) of 90 (95%CI 71-109), 54 (95%CI 50-59), 34 (95%CI 26-43), 21 (95%CI 17-25), and 13 months (95%CI 11-15), respectively (P? |*Hematopoietic Stem Cell Transplantation [MESH] |Antimetabolites, Antineoplastic/*therapeutic use [MESH] |Azacitidine/*therapeutic use [MESH] |Female [MESH] |Humans [MESH] |Male [MESH] |Middle Aged [MESH] |Myelodysplastic Syndromes/mortality/pathology/*therapy [MESH] |Practice Guidelines as Topic [MESH] |Research Design [MESH] |Retrospective Studies [MESH] |Risk Factors [MESH] |Survival Analysis [MESH]Validation of the revised International Prognostic Scoring System in t(epmc).pdf DeepDyve Pubget Overpricing